pharmaceutical-technology.com
J&J gains FDA approval for Tremfya to treat Crohn's disease - Pharmaceutical Technology
A newly FDA-approved biologic (guselkumab/Tremfya) offers another treatment option for adults with moderate to severe Crohn’s disease, including both IV and SC induction choices. This could matter for patients who have not responded to or tolerated other therapies.
Adults with Crohn’s disease, patients currently on or considering biologics, gastroenterologists, and clinical researchers following IBD drug development.
What To Know
The FDA approved Tremfya (guselkumab) for adults with moderately to severely active Crohn’s disease, adding both subcutaneous and intravenous induction options.
Approval was supported by multiple Phase III trials (including the GRAVITI and GALAXI programmes) involving more than 1,300 participants and pooled analyses that reportedly showed superiority versus ustekinumab (Stelara) on certain endoscopic endpoints.
Tremfya is already approved for ulcerative colitis; this decision represents a new Crohn’s disease indication and gives clinicians and patients an additional biologic option with flexible induction routes. The article emphasizes trial endoscopic and clinical endpoints but does not provide detailed efficacy or safety statistics in the text.
If you are considering treatment changes, discuss with your gastroenterologist whether guselkumab could be appropriate given your disease history, prior therapies, and safety considerations. This approval is a regulatory update rather than treatment guidance.
This is a regulatory approval based on Phase III trials; the article summarizes trial programmes and pooled analyses but does not list detailed efficacy or safety data. It does not replace clinical advice. Pooled superiority versus ustekinumab is reported here but readers should consult full trial publications or regulatory documents for detailed results and safety information.
